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Introduction: Substantial heterogeneity remains across studies investigating changes in gray matter in schizo-
phrenia. Differences in methodology, heterogeneous symptom patterns and symptom trajectories may contrib-
ute to inconsistent ﬁndings. To address this problem, we recently proposed to group patients by symptom
dimensions, which map on the language, the limbic and the motor systems. The aim of the present study was
to investigate whether patients with prevalent symptoms of emotional dysregulation would show structural
neuronal abnormalities in the limbic system.
Method: 43 right-handed medicated patients with schizophrenia were assessed with the Bern Psychopathology
Scale (BPS). The patients and a control group of 34 healthy individuals underwent structural imaging at a 3TMRI
scanner. Whole brain voxel-based morphometry (VBM) was compared between patient subgroups with differ-
ent severity of emotional dysregulation. Group comparisons (comparison between patients with severe emo-
tional dysregulation, patients with mild emotional dysregulation, patients with no emotional dysregulation
and healthy controls) were performed using a one way ANOVA and ANCOVA respectively.
Results: Patients with severe emotional dysregulation had signiﬁcantly decreased gray matter density in a large
cluster including the right ventral striatum and the head of the caudate compared to patients without emotional
dysregulation. Comparing patients with severe emotional dysregulation and healthy controls, several clusters of
signiﬁcant decreased GM density were detected in patients, including the right ventral striatum, head of the
caudate, left hippocampus, bilateral thalamus, dorsolateral prefrontal and orbitofrontal cortex. The signiﬁcant
effect in the ventral striatum was lost when patients with and without emotional dysregulation were pooled
and compared with controls.
Discussion: Decreased gray matter density in a large cluster including the right ventral striatum was associated
with severe symptoms of emotional dysregulation in patients with schizophrenia. The ventral striatum is an
important part of the limbic system, and was indicated to be involved in the generation of incentive salience
and psychotic symptoms. Only patients with severe emotional dysregulation had decreased gray matter in
several brain structures associated with emotion and reward processing compared to healthy controls. The re-
sults support the hypothesis that grouping patients according to speciﬁc clinical symptomsmatched to the limbic
system allows identifying patient subgroups with structural abnormalities in the limbic network.© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Structural alterations in cerebral gray matter have been repeatedly
reported in schizophrenia, particularly in the prefrontal cortex, the
superior temporal gyrus, the limbic system (medial temporal lobe,erms of the Creative Commons
rmits non-commercial use, dis-
original author and source are
iatry, Bolligenstrasse 111, 3060
30 9404.
er).
lished by Elsevier Inc. All rights reserhippocampus, entorhinal cortex, amygdala) as well as in the insula,
the thalamus and the cerebellum (Bora et al., 2011; Ellison-Wright
et al., 2008; Glahn et al., 2008; Horn et al., 2009). Considerable hetero-
geneity of results across studies on structural anatomy has been
noted, however (Haijma et al., 2012; Honea et al., 2008). In addition
to differences inmethodology and population demographics, heteroge-
neous symptom patterns and symptom trajectories may critically
contribute to the inconsistent ﬁndings. Furthermore, the distribution
of anatomical alterations does not yield unique hints to understand
the pathophysiology of the different symptoms associated with schizo-
phrenia. Linking dimensional assessment of behavioral domains and
mental states to brain circuitry may be necessary to progress in schizo-
phrenia research (Heckers, 2011).ved.
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come this issue. In addition to the classical consideration of positive and
negative symptoms, there is growing evidence that investigating core
symptoms may lead to meaningful results, as demonstrated for formal
thought disorder (Horn et al., 2010; McCarley et al., 1993; Shenton
et al., 1992), hallucinations (Barta et al., 1990; Gaser et al., 2004;
Nestor et al., 2007) and delusions (Pankow et al., 2012; Spencer et al.,
2007). In addition, factor analysis to psychopathology as rated with
the scales for assessment of positive and negative symptoms has been
applied to reduce symptom variance in a large patient group; this re-
sulted in distinct associations with structural alterations, e.g. between
the paranoid/hallucinatory subsyndrome and the superior temporal
cortex (Nenadic et al., 2010).
If psychopathology in schizophrenia spectrumdisorders is the result
of a functional imbalance of higher order brain systems, it should be
possible to match speciﬁc psychotic symptoms on the respective brain
functions and systems. Based on this assumption, we have developed
the Bern Psychopathology Scale (BPS) as a research instrument to
group psychotic symptoms into three biologically relevant dimensions
referring to the language, limbic and motor systems (Strik et al., 2010).
Dysfunction in the limbic system in schizophrenia is a growing area
of interest. Particularly, abnormalities in emotion processing and regu-
lation are cardinal features in psychiatric disorders (Taylor and
Liberzon, 2007). They may be pivotal to produce abnormal salience
(Kapur, 2003) and threat beliefs, possibly underlying speciﬁc psychotic
symptoms such as persecutory delusions (Freeman and Garety, 2003).
Biased emotion processing may cause aggression, suspiciousness and
poor social performance of patients with schizophrenia (Kee et al.,
2003; Phillips et al., 2003), and was associated with positive psychotic
symptoms (Abi-Dargham et al., 2000; Pankow et al., 2012). In addition,
patients with schizophrenia show aberrant functional brain activation
in neuronal regions implicated in emotion and reward processing
e.g. the amygdala, insula, anterior cingulate, orbitofrontal cortex
and ventral striatum (Aleman and Kahn, 2005; Brunet-Gouet and
Decety, 2006; Kirsch et al., 2007; Pankow et al., 2013; Schlagenhauf
et al., 2008; Walter et al., 2009).
In the light of these ﬁndings from functional brain imaging, we ex-
pected changes in limbic structures to be associated with emotional
dysregulation and delusions of threat, covered in the BPS by the affectiv-
ity dimension. Particularly, we hypothesized that gray matter volumes
in the limbic system would differ between patients presenting with
severe emotional dysregulation and patientswithout emotional dysreg-
ulation. In addition, the structural alterations in patients presenting
with severe emotional dysregulation would also differ from controls.
2. Methods
2.1. Subjects and clinical assessment
In total, 43 patients (16 women and 27 men) of the University
Hospital, Bern, Switzerland, meeting DSM IV (American Psychiatric
Association 1994) criteria for schizophrenia were included. Diagnoses
were given following thorough clinical interviews and review of all re-
cords available, however the structured clinical interview for DSM IV
(SCID)was not applied. 40 patientswere treatedwith atypical or typical
antipsychotics. Three patients were drug free at the time of the study.
Five patients received typical antipsychotics (four typical and atypical
and one only typical). A control group of 34 healthy individuals was in-
cluded (18women and 16men). All subjectswere right handed. Groups
did not differ in age or gender distribution (see Table 1). However, con-
trols had longer duration of education (t = −3.4, df = 75, p = 0.001).
Participants provided written informed consent. The protocol was
approved by the local ethics committee.
Psychopathology was assessed using the Positive and Negative Syn-
drome Scale (PANSS; Kay et al., 1987) aswell as the Bern Psychopathol-
ogy Scale. The BPS was explicitly developed as a research instrument toattribute psychotic symptoms to behavioral dimensions and the
suspected underlying brain systems, namely the language, the motor
and the limbic systems. It is neither intended as a diagnostic tool in
terms of the ICD-10 or DSM-IV categories, nor attempted to cover
every phenomenon associated with psychoses.
The affectivity dimension includes symptoms of emotional dysregu-
lation, attributed to the limbic system (http://www.puk.unibe.ch/BPS)
e.g. delusions of threat or supernatural power, tension, psychotic anxi-
ety, suspiciousness, aggressiveness or social avoidance and unpleasant
body sensations. Global severity of symptoms is rated on 7 point Likert
scales ranging from−3 (e.g. most severe psychotic anxiety) to+3 (e.g.
most severe psychotic grandiosity), whereas 0 refers to normal behav-
ior; (Strik et al., 2010). The global rating does not represent a sum
score of the single items but instead refers to a global clinical impression
after assessing the presence and severity of all items. One or two very
severe impairing signs therefore may drive the global impression,
whereasmultiplemild signsmay not sumup to high global severity rat-
ings. The major differences of the BPS compared to other psychopatho-
logical scales (e.g. the PANSS) are ﬁrst the possibility to attribute
psychotic symptoms to behavioral domains and second the dual rating
system that focuses on both single signs and the global impression.
The latter allows weighting the impact of single signs with prominent
severity.
We chose a prototypical approach to data analysis, assuming that se-
vere emotional dysregulationwas reliably related to psychosis, while the
mildest forms (+1 and−1 on the global BPS scale) may overlap with
normal or reactive emotional dysregulation. Based on this consideration
and lacking precedents to provide a rationale for the cut-offs, we deﬁned
three patient subgroups according to the severity of emotional dysregu-
lation, regardless of the direction (+ or−) on the global rating. The ﬁrst
group consisted of patients with evident and severe emotional dysregu-
lation (sED; n = 14; 7women and 7men) deﬁned by high ratings in the
global affectivity scale (≤−2 or ≥+2); the second group of patients
with less evident and mild emotional dysregulation (mED; n = 22; 5
women and 17 men; BPS global affectivity−1 or +1); the third group
of patientswith normal affectivity (no symptom of emotional dysregula-
tion, nED; n = 7; 4 women and 3 men; BPS global affectivity = 0).
Patient subgroups did not differ in duration of illness, number of epi-
sodes, chlorpromazine equivalent dosage, PANSS scores (negative, posi-
tive and total scores), duration of education, age or gender distribution
and total gray matter volume (see Table A, Supplementary data).
2.2. Structural MRI acquisition and data processing
Imaging was performed on a 3T MRI scanner (Siemens Magnetom
Trio; Siemens Medical Solutions, Erlangen, Germany) with a standard
head coil. 3D-T1-weighted (Modiﬁed Driven Equilibrium Fourier
Transform Pulse Sequence; MDEFT) images for each subject have been
obtained (Deichmann et al., 2004), providing 176 sagittal slices
with 256 × 224 matrix points with a non-cubic ﬁeld of view (FOV)
of 256 × 224, yielding a nominal isotopic resolution of 1 mm3
(i.e. 1 mm × 1 mm × 1 mm). Further scan parameters were 7.92 ms
repetition time (TR), 2.48 ms echo time (TE) and a ﬂip angle of 16° (FA).
Structural images were processed using SPM8 (Wellcome Trust
Center for Neuroimaging, London; http://www.ﬁl.ion.ucl.ac.uk/
spm). All preprocessing steps were conducted using standard proce-
dures as implemented in SPM8 (Matlab version 7, release 2008a; The
MathWorks, Inc., Natick, MA, USA), in particular the voxel-based
morphometry (VBM) toolbox. The images have been normalized,
modulated and smoothed with 8 mm full-width at half maximum
(FWHM) kernel.
2.3. Statistical analyses
Statistical tests were performed using SPM routines and SPSS 17.0
(SPSS Inc., Chicago, IL, USA). Independent two-sample t tests, one way
Table 1
Sample demographic variables.
Schizophrenia Controls t/χ2 df p-Values
No. of subjects 43a 34
Gender (% female) 62.8 37.2 1.3 1 0.354
Age (years) 34.1 ± 10.9 37.1 ± 12.3 −1.2 75 0.231
Education (years) 12.9 ± 4.0 16.2 ± 4.1 −3.4 75 0.001
PANSS total score 57.4 ± 17.3 – – – –
PANSS positive syndrome score 15.4 ± 5.7 – – – –
PANSS negative syndrome score 14.6 ± 6.4 – – – –
Chlorpromazine equivalents (mg) 457.4 ± 333.7 – – – –
Mean duration of illness (years) 8.7 ± 9.3 – – – –
Number of psychotic episodes 4.1 ± 5.1 – – – –
Gray matter volume (ml) 705.9 ± 113.1 756.9 ± 80.2 −2.2 75 0.029
a Patient subgroups: sED: n = 14; mED: n = 22; nED: n = 7;−sED: n = 6;+sED: n = 8. Severe emotional dysregulation (sED), mild emotional dysregulation (mED), and no emo-
tional dysregulation (nED).
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categorical variables betweenpatients andhealthy controls. Effects of cat-
egorical and continuous variables on GM density have been investigated
using one way ANOVAs and multiple regression analysis respectively.
The primary focus of the analyses was the effect of emotional dys-
regulation on gray matter density as derived from voxel-based mor-
phometry (VBM). Gray matter (GM) density differences were therefore
explored among patient subgroups and healthy controls (sED vs. nED,
mED vs. nED,mED vs. sED) usingwhole brain ANOVAs to VBMdata. As pa-
tients differed from controls in total GM volume and duration of educa-
tion, we calculated contrasts between patients and controls with whole
brain ANCOVAs, including total GM volume and duration of education
as covariates (sED vs. healthy controls and all patients vs. healthy controls).
In addition, for an exploratory analysis we split the group of patients
presenting with severe emotional dysregulation into two samples
according to the pole of Global Affectivity scores. We then explored
graymatter density differences between both samples and those patients
without emotional dysregulation. First, the sample of patientswith severe
emotional dysregulation on the positive pole +sED (+3, +2 BPS Global
scale scores; n = 8) was contrasted with patients without emotional
dysregulation (nED; n = 7) using whole brain ANOVA to VBM data.
Second, the sample of patients with severe emotional dysregulation on
the negative pole−sED (−3,−2 BPS Global scale scores; n = 6) was
contrasted with patients without emotional dysregulation (nED) using
whole brain ANOVA to VBM data.
The resulting sets of voxels from each contrast represent a statistical
parametric map of the t-statistic (SPM-t). We excluded all voxels with
gray matter values of less than 0.01 (absolute threshold masking). For
all statistical analyses of VBM data, we used a uniform threshold of
p b 0.001 (uncorrected) and a minimum cluster size threshold of 17
voxels has been introduced for each contrast. This threshold is equiva-
lent to a map-wise false positive rate of alpha b 0.0001 using a Monte
Carlo procedure as implemented in the AlphaSim program in the Anal-
ysis of Functional Neuroimages software package (Stepens et al., 2010).
Finally we deﬁned a post hoc region of interest (ROI) using the
cluster from the whole brain VBM group comparison (sED vs. nED) in-
cluding the right ventral striatum extending to the head of the caudate.
The ROI data was then extracted with the SPM toolbox MarsBaR (Brett
et al., 2002). Gray matter density values of the ROI were extracted
from the modulated and normalized GM images for each subject and
were compared between the patients with severe emotional dysregula-
tion and no emotional dysregulation.
3. Results
3.1. GM density in patients: severe vs. no emotional dysregulation
The whole brain analysis revealed decreased GM density within a
region including the right ventral striatum extending to the head ofthe caudate in the patients with severe limbic symptoms compared to
patients with normal affectivity (sED vs. nED). Local statistical maximum
reached a peak p-value of 0.046, FDR-corrected (MNI-coordinates:
x = 18, y = −2, z = 16; peak T-value of 7.01, and MNI-coordinates:
x = 12, y = 8, z = 4; peak T-value of 5.63; cluster size of 149 voxels,
volume: 1192 mm; x: max/min = 8/20; y: max/min = −4/12; z:
max/min = −2/18 and at: x = 14, y = 16 and z = 0). Thus, one part
of the cluster is located in the ventral striatum and the other posteriorly
in the caudate head (see Fig. 1).
For an exploratory analysis gray matter density of patients with se-
vere emotional dysregulation of both poles of the BPS vs. no emotional
dysregulationwas analyzed. To investigate the effect of paranoid threat,
we compared−sED patients with nED patients (p b 0.001 uncorrected,
minimum cluster size: 17 voxels) and detected gray matter density
differences in a cluster including the ventral striatum extending to the
head of the caudate (cluster size: 124; cluster peak at MNI-coordinates:
x = 18, y = −2, z = 16, peak T-value = 6.29, and x = 12, y = 8,
z = 4, peak T-value = 5.15), as well as in the right orbitofrontal cortex
(cluster size: 31; cluster peak at MNI-coordinates: x = 16, y = 50,
z = −8, BA 11). However, the test of the effects of the opposite direc-
tion of emotional dysregulation, i.e. grandiosity (+sED vs. nED), failed
to detect signiﬁcant differences at a threshold of p b 0.001 (uncorrected,
minimumcluster size of 17).When contrasting patientswith schizophre-
nia of the two poles of the axis +sED and –sED we found no signiﬁcant
gray matter differences.
Likewise, no differences were detected when comparing patients
with mild emotional dysregulation and the other patient groups.
3.2. GM density: severe emotional dysregulation vs. healthy controls
Several clusters of decreased GM density were detected in patients
with sED compared to healthy controls (see Table 2 and Fig. 2), includ-
ing the right ventral striatum and head of the caudate nucleus, bilateral
thalamus, dorsolateral prefrontal cortex, orbitofrontal cortex, insula and
left hippocampus.
3.3. GM density: all patients vs. controls
GM density of all patients, irrespective of the psychopathology, was
decreased in widespread and well-known brain areas, including the
right thalamus, bilateral ventral prefrontal cortex, and left superior tem-
poral gyrus compared to controls (see Table 3 and Fig. 3).
No differences in GM have been found when comparing patients
with mild emotional dysregulation and healthy controls. Results of the
contrast of patients without emotional dysregulation and healthy
controls are given in Supplementary Table B. Using an ANCOVA with
total GM volume as covariate to determine the differences across all pa-
tient subgroups and healthy controls we found GM density differences
in the right thalamus, the bilateral orbitofrontal cortex and a larger
Fig. 1.Decreased GMdensity of the ventral striatumof patients with severe emotional dysregulation. Groupmap of volumeswith lower concentration of GMwas statistically thresholded
at p b 0.001, uncorrected and displayed on the section of the standard MNI-template; minimum cluster size threshold of 17 voxels. Local difference maxima in the depicted brain region
reached a peak p-value of 0.046, FDR-corrected. GM density values in the cluster including the right ventral striatum of patients with severe and no emotional dysregulation. sED: severe
emotional dysregulation and nED: no emotional dysregulation.
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Supplementary analysis A, Fig. A, Table C).
In order to rule out the putative effects of medication and total GM
volume on our ﬁndings, we have provided additional ANCOVAs of the
contrasts with chlorpromazine equivalents and total GM volume as
covariates, which corroborated the main results (see Supplementary
material, analysis B, Table D).
In addition post hoc ANCOVA analyses were performed within the
region of interest (ROI) using the cluster from the whole brain VBM
comparison (sED vs. nED) including the right ventral striatum. Results
supported the main ﬁndings (see Supplementary material analysis C
and Fig. B).Table 2
Regions with signiﬁcant group differences in brain density (sED b healthy controls). The value
SPM maps were thresholded at p b 0.001 (uncorrected, voxel-level); minimum cluster size thr
Lobe Region
Brodmann area Anatomical region
Midbrain, thalamus L thalamus
R thalamus
Frontal lobe, superolateral, prefrontal BA 10 L middle frontal gyru
BA 10 L superior frontal gy
BA 46 L inferior frontal gyr
BA 46 R inferior frontal gyr
BA 10 R middle frontal gyr
BA 11 L middle frontal gyru
BA 11 R Middle frontal gyr
BA 11 L middle frontal gyru
BA 11 R middle frontal gyr
BA 11 L Medial orbital gyru
R medial orbital gyru
Frontal lobe, medial/inferior, prefrontal BA 10 R medial frontal gyru
Limbic lobe R ventral striatum
Caudate nucleus, hea
Hippocampal formation L hippocampus
Insular lobe BA 13 L insula
BA 13 R insula
BA: Brodmann area; R: right; L: left; MNI: Montreal Neurological Institute; sED: severe emotio3.4. Correlations of PANSS scores and BPS Global scores
Using the ﬁve-factor model (positive symptoms, negative symp-
toms, disorganization, excitement, emotional distress) of the PANSS ac-
cording to van derGaag et al. (2006) a signiﬁcant negative correlation of
the factor emotional distress and the BPS-Affectivity Global scores
(ranging from −3 to +3) has been found (r = −0.38; p = 0.012).
No signiﬁcant correlation between the other factors according to van
der Gaag and the BPS-Global scores emerged. Results of an exploratory
group analysis of the single PANSS item delusions indicated higher
scores for delusion in patients with severe emotional dysregulation
(see Supplementary material, analysis D).s given are the stereotactic (MNI) coordinates and the T values of each anatomical region.
eshold of 17 voxels.
Statistical effects




−8 −14 10 74 3.89
12 −18 12 169 4.58
s −32 54 0 77 4.57
rus −20 56 20 29 4.28
us −50 36 2 74 5.16
us 44 48 −2 41 3.89
us 40 44 12 19 3.87
s −24 34 −20 85 4.84
us 26 36 −16 72 4.19
s −36 46 18 19 3.78
us 40 44 −16 24 4.28
s/ −6 36 −26 732 4.95
s 4 46 −16 4.71
s 12 62 −2 17 4.07
12 12 −4 114 3.83
d 14 14 6 3.63
−32 −28 −8 37 4.36
−32 22 6 74 3.77
36 24 −2 99 5.21
nal dysregulation. Patients with sED, n = 14; healthy controls, n = 34.
Fig. 2.DecreasedGMdensity in patientswith severe emotional dysregulation compared to
healthy controls. Groupmap of volumes with lower concentration of GMwas statistically
thresholded at p b 0.001, uncorrected and displayed on the section of the standard MNI
brain; minimum cluster size threshold of 17 voxels.
Fig. 3. Decreased GM density of all patients compared to healthy controls. Group map of
volumeswith lower concentration of GMwas statistically thresholded at p b 0.001, uncor-
rected and displayed on the section of the standard MNI brain; minimum cluster size
threshold of 17 voxels.
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The current study aimed to testwhether patientswith schizophrenia
presenting with severe emotional disturbances would differ in terms of
GM density from patients without such emotional disturbances. In line
with our hypothesis, patients with schizophrenia with symptoms of
severe emotional dysregulation demonstrated structural alterations in
the limbic system. Particularly, graymatter density in a larger cluster in-
cluding the right ventral striatum was decreased compared to patients
without emotional dysregulation. Compared to healthy controls pa-
tients with emotional dysregulation were found to have decreased GM
density in several brain structures associated with emotion processing
such as a large cluster including the right ventral striatum and head of
the caudate, left hippocampus, bilateral thalamus, dorsolateral prefron-
tal and orbitofrontal cortex. When we compared the GM density of all
schizophrenia patients with that of all healthy controls, the focus on
the limbic system was lost, and a pattern of GM deﬁcits consistent
with previous studies in schizophrenia was found, including the right
thalamus, bilateral ventral prefrontal cortex, and left superior temporal
gyrus but not the ventral striatum (Bora et al., 2011; Ellison-Wright and
Bullmore, 2010; Ellison-Wright et al., 2008; Glahn et al., 2008; Honea
et al., 2008). The main ﬁnding suggests severe emotional disturbance
in schizophrenia to be particularly associated with reduced GM in a
large cluster including the ventral striatum. In fact, this decrease ofTable 3
Regions with signiﬁcant group differences in brain density (all patients b healthy controls). Th
region. SPM maps were thresholded at p b 0.001 (uncorrected, voxel-level); minimum cluster
Lobe Region
Brodmann area Anatomical region
Midbrain, thalamus R thalamus
Frontal lobe BA 11 L middle frontal gyrus
BA 11 L orbital gyrus,
R orbital gyrus
BA 10 R medial frontal gyrus
Temporal lobe BA 38 L superior temporal gyrus
BA: Brodmann area; R: right; L: left; MNI: Montreal Neurological Institute; all patients, n =
dysregulation. Patients with sED, n = 14; patients with nED: n = 7.GM in the limbic system was speciﬁc only to severe emotional distur-
bances in schizophrenia but unrelated to general cerebral changes
associated with schizophrenia.
4.1. GM alterations in regions of emotion processing
Compared to healthy controls, in emotionally disturbed patients de-
creased GM density was found in several brain structures that are asso-
ciated with emotion processing and reward processing via a limbic
cortico–striato–pallido–thalamic circuit that is closely associated with
the mesolimbic dopamine pathway (for review see Dichter et al.,
2012). Speciﬁcally, the dorsolateral prefrontal cortex has consistently
been associated with cognitive control processes such as top-down
modulation of task-relevant information processing and is considered
a key area for the integration of sensory information with behavioral
intentions, rules and rewards (Cieslik et al., 2012). The most ventral
part of the caudate has traditionally been suggested as part of the limbic
system (Alexander et al., 1990) and recently Arsalidou et al. (2012)
provided a topographical model suggesting that reward is processed
in the anterior caudate head while superior structures in the caudate
body and putamen are active during emotion processing (elicitation
and perception). Regarding the orbitofrontal cortex there is growing ev-
idence for its critical role in reward processing (Levy and Glimcher,
2012). Thus, the regions with reduced GM density in sED compared toe values given are the stereotactic (MNI) coordinates and the T values of each anatomical
size threshold of 17 voxels.
Statistical effects




10 −16 14 42 3.95
−24 34 −20 49 4.28
−4 40 −22 118 4.21
4 48 −20 3.34
10 60 0 19 3.88
−26 14 −38 327 4.19
43; healthy controls, n = 34. sED: severe emotional dysregulation; nED: no emotional
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However, GM reductions in the thalamus and orbitofrontal cortex
are less speciﬁc as GMwas also reduced when comparing all patients
vs. controls. Gray matter density reductions of the dorsolateral pre-
frontal cortex and the hippocampus have been repeatedly reported
in patients with schizophrenia independent of speciﬁc symptoms
(Bora et al., 2011; Ellison-Wright and Bullmore, 2010; Ellison-
Wright et al., 2008; Glahn et al., 2008; Honea et al., 2008). Our results
therefore corroborate the numerous ﬁndings of unspeciﬁc GM deﬁ-
cits in schizophrenia, while the larger cluster including the ventral
striatum seems to be speciﬁcally related to the affectivity dimension.
In other words: our focus on emotional dysregulation when assessing
state psychopathology allowed for the identiﬁcation of speciﬁc gray
matter alterations in a biologically plausible brain system, i.e. the limbic
system.
4.2. The ventral striatum and psychotic symptoms
Several studies assessed ventral striatum dopamine dysfunction in
schizophrenia (Hietala et al., 1995; Kumakura et al., 2007; Laruelle
et al., 1996; McGowan et al., 2004; Meyer-Lindenberg et al., 2002;
Reith et al., 1994; Wong et al., 1986). Dopamine dysfunction is one of
the core theories that aim to explain the neurobiological correlates of
schizophrenia and speciﬁc symptoms (Pankow et al., 2012). Speciﬁcally
increased, chaotic ﬁring of dopaminergic neurons in the ventral
striatum may lead to incentive salience to irrelevant stimuli, which is
supposed to be involved in the generation of delusional mood and
delusions of reference and may thereby lead to suspiciousness, ag-
gressiveness and delusions of persecution (Heinz, 1999; Heinz and
Schlagenhauf, 2010; Heinz et al., 1998; Kapur, 2003; Laruelle and
Abi-Dargham, 1999; Morrison and Murray, 2009). The applied Bern
Psychopathology Scale groups these symptoms into the domain of
affectivity, referring to emotional dysregulation and the limbic system
(Strik et al., 2010). Therefore, our results of altered GM in the ventral
striatum in the patients with severe emotional dysregulation support
the notion of an association between ventral striatal dysfunction and
delusions in schizophrenia.
4.3. Possible explanations for variance of emotional symptoms
In the light of these previous ﬁndings, our results can be interpreted
as an indication of a structural pathology in a key region involved in
emotion processing, which may have a crucial role in triggering
psychotic symptoms with high emotional valence in both positive
(e.g. grandiosity) and negative (e.g. persecutory delusions) directions.
Further studies need to demonstrate whether the detected structur-
al differences for both poles of the axis may reﬂect the “trait” of the
neuronal system while the direction (paranoid threat vs. grandiosity)
may possibly reﬂect the systems' “state”, if we assume that the affective
content may change over time. Marneros et al. (1992) found that
most of the schizophrenia patients (76%) presented a bimorphous
course i.e. showing positive and negative symptomatology according
to the Andreasen's criteria of positive and negative and mixed symp-
tomatology during the course of the illness. Likewise, different emotion-
al contents of both poles (paranoid threat and grandiosity) may be
present at the same time. Garety et al. (2013) reported considerable
overlap of grandiosity and persecutory delusions in the same patients.
When we explored the impact of the direction of severe emotional
dysregulation on brain structure, we found reduced graymatter density
in a region including the ventral striatum and the orbitofrontal cortex
exclusively for the negative pole (−sED), i.e. threat. However, this
exploratory ﬁnding has to be interpreted with caution given the limita-
tions of such analyses.
We may hypothesize that alterations in striatal GM may represent
structural changes following speciﬁc severe symptoms. In fact, several
studies described activity-dependent selective changes in gray matter(Draganski et al., 2004; Maguire et al., 2000). These structural changes
may occur even after short time periods (May and Gaser, 2006; May
et al., 2007). For instance symptoms such as delusions are likely to
cause structural changes as they seem to persist in most patients over
at least ten weeks (Appelbaum et al., 2004). Thus, the major structural
ﬁnding of decreased ventral striatal gray matter density in our study
could reﬂect structural adaption to the present symptoms of emotional
dysregulation. On the other hand, structural alterations may cause the
symptoms that we now associated with structural changes in this
cross-sectional study. However, longitudinal studies are necessary to
clarify whether the structural alterations in the ventral striatum vary
over time and whether different changes are found during the course
of the disease (Howes and Kapur, 2009).
4.4. Laterality of GM alterations of the ventral striatum
Emotional processing is considered to be lateralized (attributed) to
the non-dominant hemisphere. In addition, right/left asymmetry of do-
pamine deﬁcitsmay impact emotion processing in patientswith schizo-
phrenia (Hietala et al., 1999; Morris et al., 2012; Murray et al., 2008).
Subcortical structures of the limbic system such as the hippocampus,
the amygdala and the habenula display somedegree of structural asym-
metry (Pedraza et al., 2004; Shi et al., 2009). These asymmetries of the
human brain were interpreted as hemispheric specialization. The de-
scription of deviation from such a functional asymmetry may help to
understand the pathophysiology of patients with schizophrenia. For in-
stance abnormal asymmetry has been proposed as a risk factor, genetic
marker and possible endophenotype (Woolard and Heckers, 2012). The
structural changes in patients with severe emotional dysregulation in
our study were present unilaterally in the right ventral striatum.
Likewise, Hietala et al. (1999) speciﬁcally observed more pronounced
presynaptic dopamine dysfunction and paranoid symptoms correlated
more markedly with right hemispheric changes. These are interesting
results since they correlate abnormal lateralization and speciﬁc psy-
chotic symptoms. The direction of association, however, remains un-
clear. Lateralization may be a cause or consequence of some psychotic
symptoms that may provoke speciﬁc psychotic symptoms. On the
other hand it can be hypothesized that psychotic symptoms may be
triggered by abnormal functional or structural lateralization.
4.5. Strengths and limitations
The strength of the study is that patients were speciﬁcally grouped
according to clear-cut symptoms of emotional dysregulation (patients
with severe emotional dysregulation and patients without emotional
dysregulation). The patient subgroups did not differ in duration of
illness, chlorpromazine-equivalents, number of episodes, age of onset
or PANSS ratings (positive, negative or total). Therefore, the structural
ﬁndings in the limbic system are likely to be related speciﬁcally to the
presence of severe emotional dysregulation rather than to general clin-
ical differences. A possible limitation of the study is an effect of current
and past antipsychotic treatment, which may affect brain structure.
There is an ongoing discussion on the inﬂuence of medication on gray
matter volume. In particular, typical versus atypical antipsychotics,
dosage and treatment duration have been hypothesized as partly re-
sponsible for brain volume changes (Navari andDazzan, 2009).With re-
spect to subcortical structures, volumes of the thalamus and putamen
were detected as positively correlatedwith the degree of positive symp-
toms in unmedicated patients with schizophrenia (Gur et al., 1998; Rao
et al., 2010). These ﬁndings are particularly important since they point
to subcortical volume changes independent of treatment and possibly
dependent of psychopathology. However, in our study, all patients were
on a stable medication with ﬁrst- or second-generation antipsychotics,
except for three patients who were drug free. Further, antipsychotic
dose neither differed between the compared patient subgroups, nor
affected the main ﬁnding when entered as a covariate. Diagnoses
238 K. Stegmayer et al. / NeuroImage: Clinical 4 (2014) 232–239were given after thorough clinical psychiatric examination and chart
review; however, SCID was not applied.4.6. Conclusion
Using the BPS affectivity domain, we identiﬁed a subgroup of
patients with schizophrenia with severe emotional disturbances. On a
structural level, this grouphad particular deﬁcits in the ventral striatum,
which was absent in the other subgroup without emotional dysregula-
tion. The results intriguingly provide further evidence that the biological
and clinical heterogeneity of schizophrenia can be disentangled by
speciﬁc symptom dimensions. As previously shown in the case of hallu-
cinations, formal thought (Horn et al., 2010; Hubl et al., 2004; Strik et al.,
2008) and movement disorders (Bracht et al., 2012; Walther and Strik,
2012; Walther et al., 2011), this strategy helps to ﬁnd meaningful links
of psychopathological features with speciﬁc, well known brain systems.
The present study suggests that structural deﬁcits in the ventral stria-
tum contribute to severe emotional dysregulation in schizophrenia.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nicl.2013.12.007.References
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